Abstract
Research Overview
This analysis is available through our Drug Discovery Technologies Growth
Partnership Services program. With this program, clients receive
industry-leading market research such as this, along with technical and
econometric data and many interactive features including Analyst Inquiry Time
and Client Councils.
Technologies
The following technologies are covered in this research:
- Custom, pre-designed, or validated siRNA; siRNA sets; genome-wide
libraries;
- shRNA; expression cassettes; miRNA
- Lipid-based transfection reagents; RNAi-specific transfection reagents;
- electroporation devices and buffers; viral vectors; nano-particle
technologies
- Quantitative real time PCR assays; Northern blot kits; gene expression
arrays;
- western blot kits; 2D gel electrophoresis consumables; proteomics arrays;
- phenotypic assays
Market Overview
The U.S. RNAi markets are rapidly evolving as a growing number of scientists
transition their research focus from low-throughput to medium- and
high-throughput in one dimension, and from in vitro to in vivo in a second
dimension. Numerous opportunities exist for vendors of RNAi content and tools,
especially as technologies advance to provide greater selectivity and
specificity of knockdown. RNAi technologies are proving to be indispensable
tools for functional genomics research and for identifying and validating
potential drug targets. RNAi has become a vital tool for examining both gene
and protein expression analyses, especially with regards to understanding the
pre- and post-transcriptional function of genes in relation to disease. Using
RNAi, researchers are able to simply turn genes on and off and observe what
happens, thereby gaining insights into how genes participate in cellular
processes. RNAi is by far the most widely used gene-silencing technique
employed in research.
View Cart
